Skip to content
  • Argentina
  • Brazil
  • Canada
  • Chile
  • Colombia
  • Europe
  • France
  • Germany
  • India
  • Italy
  • Japan
  • Korea
  • Mexico
  • Perú
  • Russia
  • Spain
  • Taiwan
  • The Middle East
  • Turkey
  • United Kingdom
  • United States
  • Vietnam
  • Italia
    • Utenti registrati
    • 0039 0424-472449 Richiedi informazioni
    • 0039 0424-472449 Richiedi informazioni
    ItalyItaly
      • Part of brands: |
        • Guida
          • Prevenzione di malattie ereditarie
          • Gravidanza serena
        • I nostri servizi
          • Per gli specialisti della salute
          • Per i pazienti
        • Diagnostica
        • Chi Siamo
          • Igenomix Research
          • Chi siamo
        • Webinars
        Genomics Precision Diagnostic > Oncology > Oncology Hereditary Breast Cancer

        Hereditary Breast Cancer

        Breast cancer is the most common malignancy among females and the second most common cause of death from a neoplastic disease affecting women. 
        Overview
        Indication
        Clinical Utility
        Genes & Diseases
        Methodology
        References

        Overview

        • Breast cancer is the most common malignancy among females and the second most common cause of death from a neoplastic disease affecting women. Up to 5%-10% of breast cancer cases are hereditary and are caused by pathogenic mutations in genes such as BRCA1 and BRCA2 as well as germline mutations in other high penetrant genes. Nonetheless, some of these genes have been associated with other cancers, such as ovarian, pancreatic and colorectal cancer. 
        • Hereditary cancer syndromes are encountered in all medical specialties. Although they account for about 5% of all malignancies, it is of special importance to identify these patients because, unlike patients with sporadic cancers, they require special, long-term care as their predisposition can cause them to develop certain tumors at a relatively early age. These cancers can arise in the lungs, kidneys, liver, pancreas, skin, eyes, heart. Most hereditary cancers are associated with a “germline mutation” that will be present in every cell of the human body. Identification of patients at risk of inherited cancer susceptibility is dependent upon the ability to characterize genes and alterations associated with increased cancer risk as well as gathering a detailed personal and family history aiding in the identification of the mode of inheritance as well as other family members at risk of suffering from this susceptibility. Most of these genes are inherited in an autosomal dominant fashion.  
        • The Igenomix Hereditary Breast Cancer Precision Panel can be used as a screening and diagnostic tool ultimately leading to a better management and prognosis of the disease. It provides a comprehensive analysis of the genes involved in this disease using next-generation sequencing (NGS) to fully understand the spectrum of relevant genes involved, and their high or intermediate penetrance. 

        Indication

        The Igenomix Hereditary Breast Cancer Precision Panel is indicated in those cases where there are:  

        • Individuals with personal history of breast/ovarian cancer and one of the following 
        • Breast and/or ovarian or pancreatic cancer in at least two blood relatives. 
        • Multiple primary breast cancers or bilateral breast cancer first diagnosed before the age of 50 years. 
        • Premenopausal triple negative breast cancer diagnosed at a young age (<45 years). 
        • Male breast cancer in a blood relative. 
        • Ethnicities with high BRCA mutation frequency, such as Ashkenazi Jews, should be tested, even in the absence of family history. 

        Clinical Utility

        The clinical utility of this panel is:  

        • The genetic and molecular diagnosis for an accurate clinical diagnosis of a patient with personal or family history suggestive of hereditary breast cancer.  
        • Early initiation of treatment with a multidisciplinary team for appropriate surveillance, chemoprevention and risk-reducing mastectomy (RRM) or risk-reduction salpingo-oophorectomy.  
        • Risk assessment of asymptomatic family members according to the mode of inheritance  
        • Reduce morbidity related to breast cancer or morbidity secondary to complications of surveillance and treatment. 
        • Improved pathways from diagnosis to treatment in susceptible populations. 

        Genes & Diseases

        Methodology

        References

        See scientific referrals

        Paul, A., & Paul, S. (2014). The breast cancer susceptibility genes (BRCA) in breast and ovarian cancers. Frontiers in bioscience (Landmark edition), 19, 605–618. https://doi.org/10.2741/4230 

        Yamauchi, H., & Takei, J. (2018). Management of hereditary breast and ovarian cancer. International journal of clinical oncology, 23(1), 45–51. https://doi.org/10.1007/s10147-017-1208-9 

        Apostolou, P., & Fostira, F. (2013). Hereditary breast cancer: the era of new susceptibility genes. BioMed research international, 2013, 747318. https://doi.org/10.1155/2013/747318 

        National Comprehensive Cancer Network.  (2021). Retrieved from https://www.nccn.org/professionals/physician_gls/default.aspx#detection  

        Hereditary Breast and Ovarian Cancer. (2021). Retrieved 16 February 2021, from https://www.cancer.net/cancer-types/hereditary-breast-and-ovarian-cancer 

        Cao, A., Huang, L., & Shao, Z. (2017). The Preventive Intervention of Hereditary Breast Cancer. Advances in experimental medicine and biology, 1026, 41–57. https://doi.org/10.1007/978-981-10-6020-5_3 

        descargar

        Detail description

        Download

        BROCHURE

        Download

        Request Information


        • reCAPTCHA demo: Simple page

        GUIDA

        Fertilità
        Prevenzione di malattie ereditarie
        Gravidanza serena

        I NOSTRI SERVIZI

        Soluzioni genetiche
        Informazioni sulla genetica

        PANORAMICA

        Informazioni su Igenomix
        Contatti
        Come inviare un campione
        Qualità
        Lavora con noi
        News and Press

           0039 0424-472449
        Contatti
        • Argentina
        • Brazil
        • Canada
        • Chile
        • Colombia
        • Europe
        • France
        • Germany
        • India
        • Italy
        • Japan
        • Korea
        • Mexico
        • Perú
        • Russia
        • Spain
        • Taiwan
        • The Middle East
        • Turkey
        • United Kingdom
        • United States
        • Vietnam
        Linguaggio

        [2019] © Igenomix Politica sulla privacyPolitica qualità Politica dei cookie       Soddisfazione       Manuale dell’utente

        Richiedi informazioni








        • reCAPTCHA demo: Simple page











        • Guida
          • Prevenzione di malattie ereditarie
          • Gravidanza serena
        • I nostri servizi
          • Per gli specialisti della salute
          • Per i pazienti
        • Diagnostica
        • Chi Siamo
          • Igenomix Research
          • Chi siamo
        • Webinars
        • Italia
        • Utenti registrati
        • Area pazienti
        • Area cliniche

        We are using cookies to give you the best experience on our website.

        You can find out more about which cookies we are using or switch them off in settings.

        Italy
        Powered by  GDPR Cookie Compliance
        Privacy Overview

        This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

        Strictly Necessary Cookies

        Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

        If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.